The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT

Bone Marrow Transplantation

Volumn 43, Issue 1, 2009, Pages 29-36

  Luo, X H ^a   Chang, Y J ^a   Xu, L P ^a   Liu, D H ^a   Liu, K Y ^a   Huang, X J ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CD14 SELECTION; CD34 SELECTION; CD4 CD8 RATIO; CELL SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IN VITRO STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPHIL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; CHILD; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58549098891     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.267     Document Type: Article

References (38)

1. Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH et al Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17: 869-875.
2. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
3. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
4. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770-773.
5. Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005; 105: 2300-2306.
6. Tanaka J, Mielcarek M, Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood 1998; 91: 347-352.
7. Zaucha JM, Gooley T, Heimfeld S. The ratio of CD3: CD14 cells and the number of CD34 cells in G-CSF mobilized peripheral blood mononuclear cell (G-PBMC) products are significantly associated with clinical outcome in HLA-identical sibling transplantation. Blood 2000; 96 (Suppl 1): 205a.
8. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: Significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186-3191.
9. Ji SQ, Chen HR, Wang HX, Yan HM, Pan SP, Xun CQ. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 261-267.
10. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297.
11. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073.
12. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol 2006; 135: 423-437.
13. Tabilio A, Falzetti F, Zei T, De Ioanni M, Bonifacio E, Battelli F et al. Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 274-280.
14. Chen SH, Li X, Huang XJ. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004; 79: 178-184.
15. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89: 1517-1524.
16. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007; 17: 193-197.
17. Liu Y, Chen S, Yu H. Standardization and Quality Control in Flow Cytometric Enumeration of CD34(+) cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2000; 8: 302-306.
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204.
20. Katz MH. Multivariable Analysis: A Practical Guide for Clinicians, 2nd edn. Cambridge University Press: Cambridge, 2006.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
22. Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: Should 2 × 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489-496.
23. Slowman S, Danielson C, Graves V, Kotylo P, Broun R, McCarthy L. Administration of GM-/G-CSF prior to bone marrow harvest increases collection of CD34+ cells. Prog Clin Biol Res 1994; 389: 363-369.
24. Anasetti C, Heimfeld S, Rowley S, Martin PJ, Petersdorf EW, Woolfrey A et al. Higher CD34 cell dose is associated with improved survival after marrow transplantation from unrelated donors. Blood 1999; 94 (S1): 2509a.
25. Morariu-Zamfir R, Rocha V, Devergie A, Socie G, Ribaud P, Esperou H et al. Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 2001; 27 575-580.
26. Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608-1616.
27. Lickliter JD, McGlave PB, DeFor TE, Miller JS, Ramsay NK, Verfaillie CM et al. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation. Bone Marrow Transplant 2000; 26: 723-728.
28. Zaucha JM, Zellmer E, Georges G, Little MT, Storb R, Storer B et al G-CSF-mobilized peripheral blood mono-nuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 2001; 7: 613-619.
29. Bacigalupo A, Van Lint MT, Occhini D, Margiocco M, Ferrari G, Pittaluga PA et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988; 45: 1091-1094.
30. Stussi G, Muntwyler J, Passweg JR, Seebach L, Schanz U, Gmur J et al Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 87-93.
31. Martins SLR, St. John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 2004; 104: 3429-3436.
32. Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Villard F et al. A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. Leukemia 2006; 20: 1557-1565.
33. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-1297.
34. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125: 435-454.
35. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev 2006; 20: 15-27.
36. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903-2911.
37. van den Brink MRM, Moore E, Ferrara JLM, Burakoff SJ. Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation 2000; 69: 446-449.
38. Dong L, Wu T, Zhang MJ, Gao ZY, Lu DP. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007; 13: 1515-1524.